Kyverna Therapeutics, Inc. Common Stock (KYTX)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Headquarters
- United States
- Employees
- 129
- Market Cap
- $455M
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
SentiSense also tracks daily options readings for Kyverna Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Kyverna Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.